Synonym
Firzacorvir; ABI-H2158; ABIH2158; ABI H2158
IUPAC/Chemical Name
(3S,5R)-N-(3-chloro-4-fluorophenyl)-2-methyl-5-[5-(1-methyl-1Himidazol-
4-yl)-1,3-thiazol-2-yl]-1,1-dioxo-1λ6,2,6-thiadiazinane-3-
carboxamide
InChi Key
XVKTYEAUJPZPDZ-HIFRSBDPSA-N
InChi Code
InChI=1S/C18H18ClFN6O3S2/c1-25-8-14(22-9-25)16-7-21-18(30-16)13-6-15(26(2)31(28,29)24-13)17(27)23-10-3-4-12(20)11(19)5-10/h3-5,7-9,13,15,24H,6H2,1-2H3,(H,23,27)/t13-,15+/m1/s1
SMILES Code
FC1=C(Cl)C=C(NC([C@H]2N(C)S(N[C@@H](C3=NC=C(C4=CN(C)C=N4)S3)C2)(=O)=O)=O)C=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
484.95
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Yan R, Cai D, Zong Y, Guo L, Zhou Y, Tang A, Li L, Huang Q, Colonno R, Walker
MA. Preclinical characterization of ABI-H2158, an HBV core inhibitor with dual
mechanisms of action. Antiviral Res. 2023 Jan;209:105485. doi:
10.1016/j.antiviral.2022.105485. Epub 2022 Dec 9. PMID: 36509208.
2: Agarwal K, Xu J, Gane EJ, Nguyen TT, Ding Y, Knox SJ, Alves K, Evanchik M,
Zomorodi K, Ma J, Yan R, Huang Q, Colonno R, Stamm LM, Hassanein TI, Kim DJ, Lim
YS, Yuen MF. Safety, pharmacokinetics and antiviral activity of ABI-H2158, a
hepatitis B virus core inhibitor: A randomized, placebo-controlled phase 1
study. J Viral Hepat. 2023 Mar;30(3):209-222. doi: 10.1111/jvh.13764. Epub 2023
Jan 12. PMID: 36302125.